Moreover, alternative angiogenetic pathways acting via angiopoietins that are upregulated in glioblastomas receiving anti-VEGF-treatment in animal models in vivo (Scholz et al. 2015) may present further promising targets and possibilities for treatment escape mechanisms in meningiomas. This evidence concerns the gene VEGFA and glioblastoma.